Skip to main content

Table 3 Univariate and multivariate analyses in patients treated with allo-HSCT

From: High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia

Variables

EFS

OS

HR (95% CI)

P-value

HR (95% CI)

P-value

Univariate analyses

 MiR-363 (high vs. low)

1.182 (0.643–2.175)

0.590

1.424 (0.775–2.619)

0.255

 WBC (≥ 20 vs. < 20 × 109/L)

1.089 (0.594–1.999)

0.782

0.826 (0.450–1.516)

0.537

 FLT3–ITD (positive vs. negative)

1.876 (0.914–3.851)

0.086

1.973 (0.953–4.084)

0.067

 NPM1 (mutated vs. wild)

1.007 (0.515–1.970)

0.983

1.023 (0.523–1.998)

0.948

 DNMT3A (mutated vs. wild)

1.285 (0.655–2.520)

0.466

1.387 (0.704–2.731)

0.344

 RUNX1 (mutated vs. wild)

1.145 (0.449–2.290)

0.777

1.579 (0.613–4.067)

0.344

 TP53 (mutated vs. wild)

2.034 (0.718–5.760)

0.181

4.334 (1.453–12.925)

0.009

 TET2 (mutated vs. wild)

0.526 (0.127–2.186)

0.377

0.670 (0.162–2.776)

0.581

 MLL–PTD (mutated vs. wild)

5.775 (1.664–20.042)

0.006

2.728 (0.832–8.944)

0.098

 IDH1/IDH2 (mutated vs. wild)

0.587 (0.271–1.273)

0.177

0.633 (0.293–1.368)

0.245

 NRAS/KRAS (mutated vs. wild)

0.796 (0.245–2.586)

0.705

0.488 (0.150–1.587)

0.233

Multivariate analyses

 MLL–PTD (mutated vs. wild)

5.180 (1.449–18.511)

0.011

3.136 (0.943–10.429)

0.062

 FLT3–ITD (positive vs. negative)

1.837 (0.868–3.888)

0.112

2.301 (1.090–4.860)

0.029

 TP53 (mutated vs. wild)

2.493 (0.860–7.226)

0.092

5.848 (1.885–18.142)

0.002

  1. EFS event-free survival, OS overall survival, WBC white blood cell